Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
出版年份 2020 全文链接
标题
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000842
出版商
BMJ
发表日期
2020-06-24
DOI
10.1136/jitc-2020-000842
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
- (2020) Tatsuya Yoshida et al. Journal for ImmunoTherapy of Cancer
- IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1
- (2019) Emma Eriksson et al. JOURNAL OF IMMUNOLOGY
- Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
- (2019) Max Hardy-Werbin et al. OncoImmunology
- Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
- (2019) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling
- (2019) Shawn J. Rice et al. LUNG CANCER
- Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer
- (2018) Jurgita Jackute et al. BMC IMMUNOLOGY
- Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy
- (2018) Lukasz Bialkowski et al. INTERNATIONAL JOURNAL OF CANCER
- Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers
- (2018) Takaki Akamine et al. SURGICAL ONCOLOGY-OXFORD
- Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
- (2018) Samuel Rosner et al. Cancer Medicine
- C-Reactive Protein Impairs Dendritic Cell Development, Maturation, and Function: Implications for Peripheral Tolerance
- (2018) Rachel V. Jimenez et al. Frontiers in Immunology
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
- (2018) Takenobu Nii et al. CANCER RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells
- (2018) Purusottam Mohapatra et al. Molecular Oncology
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
- (2018) Alice Horisberger et al. Journal for ImmunoTherapy of Cancer
- Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer
- (2017) Ugo Pastorino et al. EUROPEAN JOURNAL OF CANCER
- Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
- (2017) Yosuke Yasuda et al. International Journal of Clinical Oncology
- Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
- (2017) Seth J. Rotz et al. PEDIATRIC BLOOD & CANCER
- A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
- (2017) Jeffrey S. Weber et al. Cancer Immunology Research
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients
- (2017) Junjie Hang et al. Scientific Reports
- The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy
- (2017) Atsuto Katano et al. Scientific Reports
- Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort
- (2017) Claudia Agnoli et al. Scientific Reports
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
- (2016) Thomas R. Flint et al. Cell Metabolism
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer
- (2016) Chunyan Zhang et al. IMMUNITY
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
- (2016) Marc Uemura et al. Journal of Hematology & Oncology
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- C-Reactive Protein Directly Suppresses Th1 Cell Differentiation and Alleviates Experimental Autoimmune Encephalomyelitis
- (2015) Lin Zhang et al. JOURNAL OF IMMUNOLOGY
- Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification
- (2015) Meredith S. Shiels et al. JNCI-Journal of the National Cancer Institute
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification
- (2015) Meredith S. Shiels et al. JNCI-Journal of the National Cancer Institute
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
- (2014) D. Gotthardt et al. BLOOD
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression
- (2014) Rickard Linnskog et al. Molecular Oncology
- IL-6 in Inflammation, Immunity, and Disease
- (2014) T. Tanaka et al. Cold Spring Harbor Perspectives in Biology
- Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy
- (2014) E. P. M. Tjin et al. Cancer Immunology Research
- Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma
- (2013) Tasnim Ara et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
- (2013) H. Tsukamoto et al. Cancer Immunology Research
- Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma
- (2012) Lise Hoejberg et al. MELANOMA RESEARCH
- Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses
- (2011) B. C. Betts et al. BLOOD
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors
- (2011) T. Iwata-Kajihara et al. JOURNAL OF IMMUNOLOGY
- Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells
- (2010) A. Herrmann et al. CANCER RESEARCH
- Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
- (2010) M. Kujawski et al. CANCER RESEARCH
- Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
- (2009) Heike Knüpfer et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling
- (2009) Peter Findeisen et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients
- (2008) Susan K. Lutgendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt
- (2008) Nicolas Manel et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started